Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O15105

UPID:
SMAD7_HUMAN

ALTERNATIVE NAMES:
Mothers against decapentaplegic homolog 8; SMAD family member 7

ALTERNATIVE UPACC:
O15105; B7Z773; K7EQ10; O14740; Q6DK23

BACKGROUND:
The protein Mothers against decapentaplegic homolog 7, alternatively known as SMAD family member 7, is integral to cellular regulation through its inhibition of TGF-beta type 1 receptor superfamily members. It functions by preventing SMAD2 access to TGF-beta and activin receptors, recruiting the PPP1R15A-PP1 complex for dephosphorylation of TGFBR1, and facilitating PDPK1 kinase activity dissociation from YWHAQ.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of SMAD7 could open doors to potential therapeutic strategies, especially in the context of Colorectal cancer 3. Its ability to influence TGF-beta signaling pathways presents a promising target for developing treatments aimed at mitigating the progression of colorectal cancer.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.